Ginseng and Ginkgo Interactions with Atorvastatin and Eliquis
Ginseng does not significantly interact with either atorvastatin or apixaban (Eliquis), while ginkgo has minimal pharmacokinetic effects on atorvastatin without clinical significance and does not meaningfully interact with apixaban.
Ginseng Interactions
With Warfarin (Not Apixaban)
The guideline evidence specifically addresses ginseng with warfarin, not DOACs like apixaban. In a prospective cohort study, ginseng did not affect warfarin clearance or INR 1. However, one research study suggests ginseng may reduce warfarin effectiveness in cardiovascular disease patients 2, though this contradicts the guideline-level evidence. The warfarin data is not directly applicable to apixaban since they work through different mechanisms (vitamin K antagonism vs. direct Factor Xa inhibition).
With Atorvastatin
No evidence in the provided literature addresses ginseng-atorvastatin interactions. Based on the lack of documented interactions and ginseng's minimal effect on CYP450 enzymes 1, no dose adjustment is needed.
Ginkgo Interactions
With Atorvastatin
Ginkgo biloba causes a modest reduction in atorvastatin plasma concentrations (AUC decreased 10-14%, Cmax decreased 29%) but does not meaningfully affect cholesterol-lowering efficacy 3. This pharmacokinetic interaction occurs through increased clearance and volume of distribution 3, but the clinical impact on lipid control is negligible. No dose adjustment of atorvastatin is required when co-administered with ginkgo.
With Apixaban (Eliquis)
The FDA label for Eliquis does not list ginkgo as a contraindicated or interacting substance 4. The label specifically addresses combined P-gp and strong CYP3A4 inhibitors/inducers, which ginkgo is not.
Important caveat: While ginkgo does not pharmacokinetically interact with apixaban, there are theoretical bleeding concerns. A 2025 study found ginkgo interactions with antiplatelet agents (clopidogrel, aspirin) were associated with increased bleeding risk and abnormal coagulation 5. However, controlled clinical studies consistently show ginkgo does not significantly impact hemostasis and does not adversely affect the safety of co-administered anticoagulants 6. The 2008 systematic review concluded that high-level safety concerns for ginkgo with anticoagulants are "unsupported by currently available evidence" 6.
Clinical Recommendations
For Atorvastatin:
- Continue both ginseng and ginkgo without dose adjustment
- Monitor lipid panels as clinically indicated (standard monitoring)
For Apixaban (Eliquis):
- Continue both ginseng and ginkgo without dose adjustment
- Monitor for bleeding signs/symptoms (bruising, hematuria, melena, excessive bleeding from minor cuts) particularly in the first 2-4 weeks of combined therapy
- Consider baseline and follow-up CBC if clinically indicated in high-risk patients (elderly, low body weight, renal impairment)
Key Pitfalls to Avoid
Do not confuse warfarin data with DOAC data: Warfarin interactions are mediated through CYP2C9 and vitamin K pathways, while apixaban is affected by P-gp and CYP3A4. Ginseng's lack of warfarin interaction does not automatically translate to DOACs, but the mechanisms suggest safety.
Do not overreact to case reports: Most ginkgo bleeding case reports involve poor-quality evidence and do not implicate standardized extracts like EGb 761 6. The controlled trial data is reassuring.
Distinguish pharmacokinetic from pharmacodynamic effects: Ginkgo's modest reduction in atorvastatin levels does not translate to reduced efficacy 3, so dose escalation is unnecessary and potentially harmful.